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Genes uniquely expressed in human
growth plate chondrocytes uncover a
distinct regulatory network
Bing Li1, Karthika Balasubramanian1, Deborah Krakow2,3,4 and Daniel H. Cohn1,2*
Abstract
Background: Chondrogenesis is the earliest stage of skeletal development and is a highly dynamic process, integrating the
activities and functions of transcription factors, cell signaling molecules and extracellular matrix proteins. The molecular
mechanisms underlying chondrogenesis have been extensively studied and multiple key regulators of this process have been
identified. However, a genome-wide overview of the gene regulatory network in chondrogenesis has not been achieved.
Results: In this study, employing RNA sequencing, we identified 332 protein coding genes and 34 long non-coding RNA
(lncRNA) genes that are highly selectively expressed in human fetal growth plate chondrocytes. Among the protein coding
genes, 32 genes were associated with 62 distinct human skeletal disorders and 153 genes were associated with skeletal
defects in knockout mice, confirming their essential roles in skeletal formation. These gene products formed a comprehensive
physical interaction network and participated in multiple cellular processes regulating skeletal development. The data also
revealed 34 transcription factors and 11,334 distal enhancers that were uniquely active in chondrocytes, functioning as
transcriptional regulators for the cartilage-selective genes.
Conclusions: Our findings revealed a complex gene regulatory network controlling skeletal development whereby
transcription factors, enhancers and lncRNAs participate in chondrogenesis by transcriptional regulation of key genes.
Additionally, the cartilage-selective genes represent candidate genes for unsolved human skeletal disorders.
Keywords: Cartilage, Chondrocyte, RNA-seq, lncRNA, Skeletal dysplasia, Gene expression, Human
Background
Chondrogenesis is the earliest stage of skeletal develop-
ment and begins during embryogenesis with the prolifer-
ation and condensation of mesenchymal cells, followed
by lineage commitment and differentiation, to yield the
chondrocytes which populate and synthesize the scaffold
for patterning the early skeletal elements. Subsequently,
growth and mineralization of endochondral bones
proceeds by establishment of the growth plates followed
by the ordered differentiation, proliferation and hyper-
trophy of growth plate chondrocytes. Most of the
terminally differentiated hypertrophic chondrocytes
undergo apoptosis, while a subset can transdifferentiate
to osteoblasts [1, 2]. Finally, the cartilage matrix is
mineralized to form bone. This highly dynamic develop-
mental process is regulated by transcription factors that
include SOX9, RUNX2 and the GLI family of proteins,
with synergistic regulation by multiple cell signaling
pathways including the fibroblast growth factor (FGF),
hedgehog, bone morphogenetic protein (BMP), trans-
forming growth factor beta (TGF-beta) and WNT signal-
ing pathways [3, 4]. Disruption of the genes that
participate in chondrogenesis can lead to inherited
skeletal disorders, as observed in humans and mice,
which are characterized by abnormalities in the forma-
tion, linear growth and/or maintenance of the skeleton.
The skeletal disorders comprise a broad range of severity
from embryonic lethal phenotypes with extensive skel-
etal abnormalities to mild disorders in which short stat-
ure and early onset osteoarthritis are the main
manifestations [5, 6].
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Systematic identification of genes expressed in cartil-
age can uncover gene regulatory networks that are
important for chondrogenesis and chondrocyte biology,
providing fundamental insight into cartilage develop-
ment and function. Indeed high-throughput gene
expression profiling followed by data mining has been
used to identify tissue-specific/selective genes in
multiple human tissues, including cartilage [7–11]. Stud-
ies in cartilage have discovered genes that are highly
and/or primarily expressed in chondrocytes and have
been used as markers to investigate the differentiation
potential of mesenchymal stem cells toward chondro-
cytes and other cell lineages [12]. Not surprisingly, a
large number of the genes selectively expressed in chon-
drocytes are associated with human skeletal disorders
[7], and the published gene expression data have been
used as a resource to facilitate studies that have led to
identification of additional genes associated with human
skeletal phenotypes. For example, TRPV4, COL11A1 and
ACAN gene mutations were identified as the causes of
autosomal dominant brachyolmia, fibrochondrogenesis
and an autosomal recessive form of spondyloepimeta-
physeal dysplasia, respectively, based in part on their
cartilage-selective (CS) expression patterns [13–15].
Microarray technology has been widely used for the
high-throughput detection of gene expression. However,
microarray gene expression applications are limited by
low signal-to-noise ratios for genes expressed at low
levels, signal saturation for highly expressed genes, and
detection restricted to a predefined gene set. The devel-
opment of high throughput sequencing methods has
facilitated measuring most cellular transcript levels by
RNA sequencing (RNA-Seq) [16]. In contrast to micro-
array technology, RNA-seq provides more sensitive and
accurate measurement of gene expression, and is able to
discover novel transcripts and genes. To provide a
deeper measure of both quantitative and qualitative gene
expression in human growth plate chondrocytes, we
used RNA-seq to acquire a comprehensive gene expres-
sion profile of the tissue. These data were complemented
by publically available RNA-Seq and ChIP-seq data sets,
also generated on high throughput sequencing plat-
forms, to reveal regulatory mechanisms that underlie
chondrogenesis and linear growth. The data have pro-
vided a comprehensive understanding of the transcrip-
tional network in chondrocytes and suggested novel
regulatory networks and mechanisms underlying chon-
drogenesis and skeletal development.
Results
Identification of cartilage-selective (CS) genes in human
fetal cartilage
We sought to identify CS genes using RNA-seq data
from human tissues and cells. Cartilage gene expression
profiles were generated from 14 to 18 week distal femur
growth plate chondrocytes. RNA-seq data from other
tissues/cells were generated by previously described
studies [17–23] and accessed from public databases as
detailed in Methods. There were 111 RNA-seq gene
expression datasets representing 22 tissues or cell types in
the comparison data set (Additional file 1: Dataset S1).
With the exception of the data from CD4+ and CD8+
primary cells, which were obtained from adults, the
remaining data were generated from human fetal tissues/
cells. Therefore, the gene expression data mainly reflected
human fetal transcription. Data quality were assessed by
calculating the Pearson’s correlation coefficients between
datasets, requiring that gene expression patterns be simi-
lar in the same or closely related tissues, which would be
reflected by high Pearson’s correlation coefficients. As
shown in Additional file 2: Figure S1, tissues/cells with
same origins had high Pearson’s correlation coefficients
and formed unique clusters, indicating that the data were
of high quality and therefore represented the intrinsic
gene expression properties of the tissues/cells studied.
Using the PaGeFinder algorithm, we identified 403
transcripts, representing 332 protein coding genes, which
were selectively expressed in cartilage (Additional file 3:
Dataset S2). A boxplot of the selective gene expression
showed that there was a set of genes that were highly
expressed in cartilage as compared with other tissues/cells
(Additional file 2: Figure S2). Many well-studied cartilage
marker genes were identified and listed as top CS genes
with high specificity measure (SPM) values, such as the
known CS genes encoding types II, IX and XI collagens,
aggrecan and matrix metalloproteinase 13 (Additional file
3: Dataset S2). We found that 63 (42%) of the CS genes
previously discovered in our similar microarray-based
study [7] were also identified as CS in the current study
(Additional file 4: Dataset S3). Another 25 genes from the
previous study [7] had high SPM values (between 0.7 and
0.9) in the current study, indicating they were preferen-
tially, but not selectively, expressed in cartilage. This com-
parison indicates that the RNA-seq approach was capable
of recapitulating the prior findings [7] and able to reveal
known and newly identified genes selectively expressed in
human fetal cartilage. There were also 57 CS genes from
the microarray study that showed expression in non-
cartilage samples in the RNA-seq dataset, reflecting the
differences between the microarray and RNA-seq tech-
niques. RNA-seq has a broader dynamic range that is able
to better detect low-abundance transcripts [24]. Thus
genes expressed at low levels on microarrays have signals
close to background and are set as non-expressed while
by RNA-seq the low level expression can be measured,
revealing that they may not be selectively expressed.
GO and KEGG pathway analysis indicated that the
cartilage-selective gene set was enriched for genes
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known to participate in skeletal system development.
These included selectively expressed genes involved in
cellular processes necessary for chondrogenesis, such as
regulation of cell proliferation and apoptosis, cellular
biosynthesis, cell adhesion, blood vessel morphogenesis,
transcriptional regulation and TGFβ signaling (Fig. 1a, b).
Cartilage-selective genes are required for skeletal
development
As the GO analysis of the CS genes indicated that they
have roles in skeletal development, it would be expected
that disruption of their functions in mice and/or humans
would lead to skeletal abnormalities. To assess this, we
retrieved mouse phenotypes from the Mouse Genome
Informatics Database (MGI, http://www.informatics.jax.-
org/) and found that mutations in 153/332 (46%) of the
CS genes were associated with mouse skeletal defects
(Fig. 1c; Additional file 3: Dataset S2). Using the MGI
descriptors, the 153 genes were represented across a
number of overlapping categories, with 128 genes associ-
ated with growth/size/body phenotypes, 92 genes associ-
ated with skeletal phenotypes, 52 genes associated with
craniofacial phenotypes, and 60 genes associated with
limb/digit/tail phenotypes. For the remaining 179 genes,
94 genes were not present in the MGI phenotype list
and 85 genes did not show a skeletal phenotype when
targeted in mice. Despite the latter observation, a review
of the literature revealed that many of these genes do
have roles in skeletogenesis, including human skeletal
disorders due to mutations in SHOX, FBLN7 and VIT as
examples [25–27]. In addition, although knockout muta-
tions targeting Trpv4 or Comp do not show skeletal
phenotypes in mice, dominant negative structural muta-
tions in these genes result in skeletal disorders in
humans [14, 28–30]. In this context, we compared the
CS genes with the genes associated with human genetic
skeletal disorders, expecting that many of the genes
would be associated with skeletal dysplasias [5]. There
were 32 of the CS genes (Additional file 3: Dataset S2)
associated with a broad spectrum of 62 human skeletal
disorders, 26 of which were also associated with mouse
skeletal phenotypes. The human and mouse skeletal
phenotypes highlight the essential roles of the CS genes
in skeletal development but also reveal that loss-of-
function mouse models do not identify the essential
roles of all genes important for skeletogenesis.
Cartilage-selective gene products interact
To decipher relationships among the proteins encoded
by the selective genes, a protein-protein interaction
network was built with Cytoscape [31]. As shown in
Fig. 2, proteins encoded by the genes showed extensive
physical interactions and formed a large interaction net-
work. Matrix metallopeptidases had complex interactions
Fig. 1 Cartilage-selective genes are required for proper bone formation. a Gene ontology (GO) analysis of cartilage-selective (CS) genes. b KEGG pathway
analysis of cartilage-selective genes. The number of genes in each GO term is indicated. c CS genes associated with skeletal phenotypes in gene targeted mice
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with extracellular matrix proteins, such as CS collagens
and aggrecan, consistent with their central roles in process-
ing these proteins and regulating bone mineralization. TGFβ
family signaling molecules including BMP2/6, ACVR1 and
GDF5 also showed physical interactions (Fig. 2), in agree-
ment with their regulatory functions in chondrogenesis and
bone formation [32]. Thus the proteins specified by the CS
genes comprise a functional cartilage interactome.
Transcriptional regulation of cartilage-selective genes
We expected that CS transcription factors could func-
tion as master regulatory molecules to control down-
stream expression of additional selectively expressed
genes. By comparing the CS genes with the transcription
factor genes annotated in the Animal Transcription Factor
Database (AnimalTFDB) [33], 34 selectively expressed car-
tilage transcription factors were identified [Figs. 1a, 2;
Additional file 5: Dataset S4]. These transcription factors
are known or now predicted to participate in multiple
cellular activities that regulate chondrocyte development
(Fig. 3a). To determine if these factors control CS gene
transcription, we searched for transcription factor binding
motifs in the promoter regions of the CS genes. As shown
in Fig. 3b, the promoters were enriched in consensus-
binding sites for transcription factors that were selectively
expressed in cartilage, including SOX6, CREB3L2, EGR2/
3/4, GLIS3, PLAGL1, RELB and SNAI1/2, all of which
have been shown to play important roles in skeletal
development [34–39]. Although RUNX2 was not identi-
fied as a CS gene, since it was also expressed in lympho-
cytes (Additional file 2: Figure S3), its binding motif was
also enriched among the CS promoters (Fig. 3b), consist-
ent with its known transcriptional regulatory role in chon-
drogenesis. These data suggest that expression of the
selective genes might be directly regulated by a group of
transcription factors that are uniquely expressed in cartilage.
The binding motif of SOX6 was also enriched among
the CS gene promoters, and SOX6 cooperates with
SOX5 to secure SOX9 binding to CS enhancers in chon-
drocytes [40]. SOX9 is expressed in skeletogenic mesen-
chymal cells at early embryonic stages and regulates
chondrogenesis through transcriptional activation of
target genes [41, 42]. SOX9 mutations in humans
produce campomelic dysplasia, a generally lethal osteo-
chondrodysplasia with distinctive abnormalities in cartil-
age and bone [43, 44]. As has been previously observed
in animal models, SOX9 is selectively expressed in cartil-
age and is required for expression of CS genes in chon-
drocytes [41, 42, 45]. In our analysis, 247 (74.4%) CS
genes had SOX9 binding sites in their promoter regions
Fig. 2 Protein-protein interaction network for the CS genes. CS proteins are represented as colored nodes. Node colors represent three GO groups
as noted
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(±2 kb of TSS). These CS genes included 25 transcription
factor genes which by ChIP-seq had SOX9 bound to their
TSS (Fig. 4a), with 13 of them showing strong SOX9
binding intensity (>25% quantile of all SOX9 binding
sites). For instance, SOX9 strongly binds to the TSS of
transcription factor genes Egr2 and Fosl1 (Fig. 4b, c),
which are essential for skeletogenesis in mice [36, 46].
Because both SOX9 and EGR2 are highly expressed and
regulate gene expression in mesenchymal stem cells
(MSC) [41, 42, 47, 48], it is plausible to speculate that
SOX9 controls chondrogenesis through functions as an
upstream transcription factor that directly activates
expression of downstream transcription factors.
Cartilage-selective genes are regulated by active
enhancers
Spatiotemporal gene expression is modulated by both tran-
scription factors and epigenetic mechanisms such as
enhancers [49]. Enhancers are distinct genomic regions
bound by transcriptional activators and are marked by
histone modifications such as histone H3 lysine 4 mono-
methylation (H3K4me1) and lysine 27 acetylation
(H3K27ac) [50, 51]. Activation of tissue-specific enhancers
provides a molecular mechanism that turns on gene
expression in a cell type-specific manner [49]. Genome-
wide studies in chondrocytes have identified a set of genes
involved in chondrogenesis that are regulated by enhancers
[52–54], so we asked whether CS gene expression might be
activated by enhancers. Active enhancers in human chon-
drocytes were predicted by mapping the genome-wide
distribution of H3K27ac [55], revealing 31,235 active chon-
drocyte enhancer regions marked by this chromatin modifi-
cation (Additional file 6: Dataset S5). By comparing these
data with enhancers across seven fetal tissues, we identified
a subset of 11,334 enhancers that were uniquely present in
chondrocytes. These enhancers were specifically enriched
at CS gene loci including COL10A1, COL2A1 and
COL11A1 (Fig. 5a and Additional file 2: Figure S4). Similar
to other tissues, the chondrocyte enhancers were predom-
inantly bound by H3K4me1 and H3K27ac (Fig. 5b, c). To
predict enhancer target genes, we examined genome-wide
enhancer-gene associations in chondrocytes with GREAT
[56]. As shown in Fig. 6a, the chondrocyte unique
enhancers were associated with genes involved in skeletal
developmental processes including bone morphogenesis,
chondrocyte differentiation, cellular carbohydrate biosyn-
thesis, polysaccharide biosynthesis and endochondral ossifi-
cation. 176 (53%) of the CS genes had active chondrocyte
unique enhancers flanking their loci, suggesting that these
genes are potentially enhancer regulated.
Fig. 3 Cartilage-selective transcription factors and DNA binding motif analysis. a ClueGO network analysis for enrichment biological process
modules within transcription factors. GO terms are represented as large nodes and genes are represented as small nodes. Node colors represent
GO groups. b Transcription factor DNA binding motif analysis shows enrichment of motifs in cartilage-selective gene promoters. All P values for
motif enrichment are less than 10−10
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With DNA motif analysis, we found that the chondro-
cyte unique enhancers were enriched for consensus-
binding sites for transcription factors that have pivotal
roles in chondrogenesis, including RUNX2, SOX8/9,
SMAD3, STAT1/4 and FOSL1 (Fig. 6b), in agreement
with the fact that they regulate transcription in part
through binding to enhancers [52, 54, 57–60]. Further-
more, binding sites for additional transcription factors
were also found to be enriched among the chondrocyte
unique enhancers, suggesting roles in transcriptional
regulation in chondrocytes that could be further
explored experimentally (Additional file 6: Dataset S5).
Identification of cartilage-selective lncRNAs
LncRNAs are emerging as transcriptional regulators that
participate in skeletogenesis through regulation of chon-
drocyte and osteoblast differentiation and homeostasis
[61]. Since most lncRNAs are polyadenylated, and there-
fore can be measured by mRNA-seq, we analyzed the
RNA-seq data and identified 34 lncRNAs genes select-
ively expressed in cartilage. LncRNAs have been shown
to act as cis-regulators that modulate expression of
neighboring genes [62, 63]. To identify potential regula-
tory targets, we used GREAT analysis to reveal protein
coding genes neighboring the cartilage selective
lncRNAs (Additional file 7: Dataset S6). Eight lncRNAs
were adjacent to genes known to be involved in skeletal
development including SOX9, GLI2, FOXA2, UMPS,
SOD2, BHLHE41 and RAB11FIP4. Three lncRNAs
(LINC00673, AC058791.1 and RP11–261P24.2) were
embedded in active enhancer regions that were marked
by H3K27ac and H3K4me1 in chondrocytes (Fig. 7a;
Additional file 2: Figure S5), suggesting the lncRNA
expression and enhancer activity might be functionally
related. Among these, we were particularly interested in
LINC00673 (annotated as a fusion gene with LINC00511
by ENSEMBL) because it is transcribed from a locus on
human chromosome 17 that is ~280 kb downstream of
SOX9. In human chondrocytes, LINC00673 was highly
expressed and its promoter was enriched in H3K4me3, a
marker for active transcription. The active enhancers at
the LINC00673 gene locus span a ~0.5 Mb region down-
stream of SOX9. This region and the upstream region of
SOX9 were marked with H3K27ac and shown to interact
with the SOX9 promoter in melanoma cells that express
SOX9 [64]. These data suggest that the LINC00673 locus
might function as an enhancer to regulate SOX9
transcription (Fig. 7a).
LINC00673 and SOX9 were highly expressed in chon-
drocytes, and also had low expression in brain, kidney,
intestine, lung, spinal cord and stomach (Fig. 7b).
Among all tissues, the expression levels of LINC00673
and SOX9 were positively correlated with each other,
yielding a Pearson’s correlation coefficient 0.66. When
we only considered the tissues/cells that express SOX9
(FPKM > 1), the Pearson’s correlation coefficient reached
0.8, indicating LINC00673 and SOX9 have orchestrated
expression patterns across tissues (Fig. 7c). To validate
the finding, we analyzed gene expression data using the
UCLA Gene Expression Tool (UGET) [65], which re-
ported the Pearson’s correlation coefficient for every pair
of 54,675 probe sets on Affymetrix HG U133 Plus 2.0
arrays from the ∼12,000 human expression profiles.
Among the 38,500 genes detected by the Affymetrix ar-
rays, SOX9 was ranked as the gene with the second
highest correlation with LINC00673 expression (the
most highly correlated gene was LINC00673 itself ), with
a Pearson’s correlation coefficient 0.43. Reciprocally,
LINC00673 was ranked as the gene that had the nine-
teenth highest correlation with SOX9 expression, with a
Pearson’s correlation coefficient 0.39. The high Pearson’s
correlation coefficients suggest a gene expression co-
regulatory mechanism between SOX9 and LINC00673
(Additional file 7: Dataset S6).
Because SOX9 positively regulates transcription
through binding to gene promoters and enhancers [54],
we also considered the possibility that SOX9 could dir-
ectly bind to LINC00673 and activate its transcription.
Fig. 4 Sox9 binds to the cartilage-selective transcription factor gene
promoters in mouse chondrocytes. a Average binding profile of
Sox9 at the CS transcription factor gene TSS. The distance on the
plot is measured in base pairs. b, c Genome browser views of Sox9
peaks along the Egr2 b and Fosl1 c loci
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To assess this, we examined SOX9 binding sites in
mouse chondrocytes [52] and found that SOX9 bound
to the promoter and structural gene for 2610035D17Rik,
the orthologue of LINC00673 in mice, strongly suggest-
ing that expression of the gene is regulated by SOX9
(Additional file 2: Figure S6). Because LINC00673 was
selectively expressed in chondrocytes and was embedded
in the enhancer region downstream of SOX9 gene, it is
also possible that there is reciprocal regulation in which
LINC00673 could work with enhancers to activate SOX9
and possibly other genes, and therefore participate in
regulation of chondrogenesis.
Discussion
Organogenesis is a process of proliferation and differen-
tiation of progenitor cells into diverse types of cells with
distinct functions. Their unique functions are largely
acquired through expression of tissue-specific/selective
genes. Studies of gene expression patterns and regula-
tory mechanisms in particular tissues thus inform our
understanding of tissue development and mechanisms of
disease. Tissue-specificity refers to genes whose expres-
sion is restricted to one particular tissue or cell type,
while tissue-selective expression includes genes that are
expressed in one or a few generally biologically similar
tissue types [66]. The data presented in this study
described 332 cartilage-selective genes expressed in
human fetal cartilage, providing unique insights into
chondrocyte gene expression and regulation.
The significance of cartilage-selective gene identification
High expression of the CS genes in chondrocytes sug-
gests they may have essential roles in skeletal develop-
ment and skeletal disorders. In support of this
hypothesis, 32 CS genes were linked to human skeletal
disorders that result from mutations in these genes.
Gene-targeting mice for 153 genes showed skeletal
development defects. Among the list, there were well-
known genes whose products have pivotal roles in chon-
drogenesis, such as cartilage collagens, cell signaling
molecules and transcription factors. Base on this obser-
vation, we suggest that some of the newly identified CS
genes may be good candidate genes for skeletal disorders
in which the associated genes have yet to be identified.
As new skeletal dysplasia loci are defined, the candidate
genes can be compared with the CS genes to promote
Fig. 5 Identification of active enhancers in chondrocytes. a Genome browser views of H3K4me1 and H3K27ac peaks along the COL10A1 locus on
chromosome 6. Chromosome coordinates are shown as black bars on top. Black arrows indicate the direction of transcription on a diagram of the
gene below. CH, chondrocytes. AG, adrenal gland. LI, large intestine. SI, small intestine. MU, muscle. SC, spinal cord. ST, stomach. TH, thymus. b and c
Genome-wide average of b H3K4me1 and c H3K27ac enrichment at chondrocyte enhancers in human fetal tissues and cells. The distance on the plot
is measured in base pairs
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rapid identification of the mutated gene. Gene network
analysis revealed complex interactions of CS gene prod-
ucts, data compatible with the hypothesis that CS genes
are functionally related in the initiation and progression
of complex diseases such as osteoarthritis. It may thus
be useful to correlate gene mutations and dysregulation
of gene expression among the chondrodysplasias with
the CS gene interactome for further understanding of
the pathogenesis of cartilage disorders [67]. In addition,
we identified 94 genes that are less studied and for
which knockout mice phenotypes have not been anno-
tated by MGI (Additional file 3: Dataset S2). According
to GO analysis, 39 of these genes are involved in cell
signaling pathways and 27 genes encode secreted pro-
teins. Their unique cartilage expression pattern suggests
the genes might participate in chondrogenesis. For
example, C2orf82 is highly expressed in human cartilage
with an average FPKM value >1500 and encodes a type I
single-pass transmembrane chondroitin sulfate proteo-
glycan. The gene showed a CS expression pattern with
the highest expression in proliferating and prehyper-
trophic zones in embryonic and postnatal growth plate.
Its expression was restricted to the uncalcified zone in
adult articular cartilage, including chondrocyte clusters
in human osteoarthritic cartilage. Its expression pattern
was similar to the highly expressed CS genes Sox9, Acan
and Col2a1, and could be induced by BMP-2, suggesting
its functions may be associated with the development
and maintenance of the chondrocyte phenotype [68]. As
a second example, zinc-finger 385 family genes including
Fig. 6 GO and DNA binding motif analysis of chondrocyte-unique enhancers. a GO analysis of chondrocyte enhancers. The number of genes in
each GO term is indicated. b Enrichment of transcription factor DNA binding motifs on chondrocyte enhancers. All P values for motif enrichment
are less than 10−10
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ZNF385B/C/D were also selectively expressed in cartil-
age and another family member, ZNF385A, was also
highly expressed in the tissue (Additional file 3: Dataset
S2). Fluorescence-labeled Znf385C protein was highly
expressed in maturing chondrocytes in the pharyngeal
arches as well as in the cartilage associated with the ear
and ventral fins in zebrafish [69]. Loss of Znf385C in
zebrafish led to craniofacial defects and premature ossifi-
cation of the Meckel’s cartilage, potentially through
disturbance of p53-dependent cell cycle regulation [69].
Therefore, targeting some of the 94 understudied CS
genes is likely to reveal new biology related to cartilage
function.
Regulation of chondrogenesis by epigenetic mechanisms
Epigenetic mechanisms such as histone modifications
and enhancers regulate transcription in skeletal develop-
ment and disease [70, 71]. Genome-wide profiling of
SOX9 indicated that it functions in part by binding to
enhancers. Disruption of upstream distal intergenic
regions especially the regions between -50 kb and
-350 kb 5′ of SOX9 by deletion/translocation/inversion
are associated with severe campomelic dysplasia [72, 73].
Systematically screening the 350 kb region upstream of
SOX9 using histone modification markers and DNase I
hypersensitivity assays identified ten potential enhancers,
with three enhancers primarily active in chondrocytes
and that activate SOX9 expression in the chondrocyte
lineage [74]. SOX9, in complex with SOX5 and SOX6,
reciprocally activate the enhancers, which provides a po-
tential mechanism for autoregulation of its own expres-
sion in chondrocytes [74]. In the current study, genome-
wide mapping of histone marks led to identification of
11,334 enhancers that were uniquely active in chondro-
cytes and associated with 176 of the CS genes. The iden-
tified active enhancers could be used as a resource to
Fig. 7 LINC00673 is co-expressed with SOX9. a Genome browser views of H3K4me1, H3K4me3, H3K27ac peaks and RNA expression track along
SOX9 and LINC00673 loci on chromosome 17 in human chondrocytes. b Bar graphs showing SOX9 and LINC00673 expression in human tissues.
Red bars indicate cartilage samples and blue bars indicate non-cartilage samples, respectively. Gene expression levels are shown as FPKM values.
c Correlation between SOX9 and LINC00673 expression (Log2FPKM) in human tissues. Scatter plot of SOX9 against LINC00673 with regression lines
showing a correlation between the two genes using the Pearson’s correlation coefficient. Red and blue dots indicates the tissues with SOX9
Log2FPKM value greater or less than 1, respectively. Cartilage samples are highlighted as purple dots. The blue regression line was generated with
data from all tissues. The red regression line was generated with data from the tissues that have SOX9 FPKM value ≥1. The Pearson’s correlation
coefficient for each regression line is shown
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explore epigenetic regulation and higher-order chroma-
tin organization in chondrocytes. The data also indicated
that these enhancers were enriched in the consensus
binding motifs for well-known transcription factors such
as SOX9 and RUNX2, suggesting that transcription
factor-bound enhancers contribute to the selective gene
expression pattern in chondrocytes.
lncRNAs and chondrogenesis
lncRNAs are non-protein coding transcripts with lengths
of more than 200 nucleotides, which are proposed to
regulate transcription through both trans- and cis-regu-
latory mechanisms. Some lncRNAs tether to their target
gene loci and affect transcriptional activity of neighbor-
ing genes through association with regulatory proteins.
They could also bind to regions on other chromosomes
and also control gene activity through recruiting regula-
tory proteins [75]. The roles for lncRNAs in skeletal
development are emerging with a growing number of
lncRNAs identified that participate in skeletal develop-
ment and disease [61]. In our study, 34 lncRNAs were
identified to be selectively expressed in human cartilage.
Eight lncRNAs are adjacent to loci of protein coding
genes that participate in skeletal development, suggest-
ing the cartilage-selective lncRNAs may be involved in
chondrogenesis through regulation of protein coding
genes. We found that LINC00673 and SOX9 are co-
regulated in human tissues, and that LINC00673 is
embedded within a potential enhancer region for SOX9,
suggesting LINC00673 may regulate SOX9 expression
through a distal enhancer. In support of this hypothesis,
by Circularized Chromosome Conformation Capture
sequencing (4C–seq), the LINC00673 locus was found to
be involved in long-range enhancer-promoter interac-
tions at the SOX9 locus in SOX9-expressed melanoma
cells but not in SOX9-inactive cells, consistent with the
enhancer-promoter interactions driving SOX9 activation
[64]. In addition, LINC00673 regulates target gene
expression in gastric cancer cells by recruiting histone
methyltransferase EZH2 and demethylase LSD1 to target
gene promoters, suggesting that it can function as a
transcriptional regulator through epigenetic mechanisms
[76]. While the exact role of LINC00673 in SOX9 gene
regulation is unknown, loss- and gain-of-function exper-
iments could be used to directly address this question.
Cartilage-selective genes and mouse phenotypes
There were 85 CS genes that did not show a skeletal
phenotype when targeted in mice (Figure 1C). Some of
these genes may have overlapping functions with paralo-
gous genes. For example, NKX3.1 is a transcription
factor selectively expressed in cartilage. Inactivation of
the Nkx3.1 gene produced no apparent skeletal pheno-
type, while knockout of its paralogue Nkx3.2 in mice led
to a lethal skeletal dysplasia, with abnormalities of the
vertebral column and craniofacial bones [77–80]. Nkx3.1
and Nkx3.2 double knockout mice showed enhanced
vertebral defects compared with Nkx3.2 knockout mice,
suggesting that Nkx3.1 and Nkx3.2 regulate skeletal
development coordinately [81]. In addition, although
knockout of some CS genes did not produce skeletal
defects in mice, such mutations in humans produced
skeletal disorders. As an example, knockout of Wisp3 in
mice did not yield skeletal abnormalities, while human
loss-of-function mutations in WISP3 produce the auto-
somal recessive skeletal disease progressive pseudorheu-
matoid dysplasia in humans (OMIM 208230). Depletion
of the gene in zebrafish affected mandibular and
pharyngeal cartilage development and over-expression
Wisp3 in zebrafish indicated that it might function as a
BMP and Wnt signaling modulator [82, 83]. As another
example, COMP encodes a noncollagenous extracellular
matrix protein that interacts with cartilage collagens and
promotes formation of well-defined collagen fibrils [84].
In contrast to COMP knockout mice, which showed
normal skeletal development, dominant missense muta-
tions of human COMP result in autosomal dominant
pseudoachondroplasia and multiple epiphyseal dysplasia
type 1 [29, 85, 86]. Furthermore, pseudoachondroplasia
knock-in mice carrying the COMP p.Thr583Met muta-
tion that causes a skeletal phenotype in humans exhib-
ited short-limb dwarfism and severe degeneration of
articular cartilage [87]. COMP p.Asp469del knock-in
mice developed a progressive short-limb dwarfism and
hip dysplasia, with disorganized growth plate [88].
Finally, dominant structural mutations in TRPV4, which
encodes a Ca2+ permeable ion channel that responds to
chemical and physical stimuli, result in a broad
spectrum of inherited skeletal disorders in humans
[14, 28, 89–91]. Trpv4 knockout mice showed bladder
dysfunction and hearing loss without obvious skeletal
defects [92]. However, Trpv4 transgenic mice expressing
the known pathogenic missense mutation p.Arg594His
showed a severe skeletal dysplasia that recapitulated
abnormalities of metatropic dysplasia in humans [93]. In
the latter examples, dominant negative or gain-of-
function mutations interrupt normal chondrocyte activ-
ities and lead to abnormal skeletal phenotypes that mouse
knockouts did not reveal.
Limitations and future directions
The goal of this study was to identify key genes and
transcriptional regulatory mechanisms in chondrogene-
sis using total RNA isolated from fetal distal femur
cartilage, including all types of chondrocytes from the
growth plate. As a consequence, we were not able to
determine if the selective genes are uniformly expressed
throughout the growth plate or are preferentially
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expressed in certain chondrocyte cell type(s). For ex-
ample, it is known that SOX9 is expressed in reserve and
proliferating chondrocytes and COL10A1 is expressed in
hypertrophic chondrocytes [94, 95]. Laser capture
microdissection followed by RNA-seq could further
define the expression patterns of the cartilage-selective
genes. In addition, due the limited number of tissue
types and samples used in this study, and objective but
arbitrary criteria for identifying cartilage selectivity, the
CS gene list could change if the criteria for identifying
CS selective genes are changed, or as additional fetal
tissue expression profiles are added. Curation of
additional RNA-seq data from human tissues and devel-
opmental stages will help to better define tissue selective
genes and promote functional studies at spatial and
temporal scales.
Conclusions
In summary, the current study identified 332 protein
coding genes and 34 lncRNA genes that are selectively
expressed in human fetal cartilage. Proteins transcribed
from the cartilage-selective genes formed a complex
interaction network and participate in multiple processes
in skeletal development. The data further indicate that
transcription factors, enhancers and lncRNAs work
cooperatively to mediate transcriptional regulation in
cartilage. In addition to known regulatory molecules,
our study also discovered novel protein coding genes
and lncRNAs that are likely to regulate chondrogenesis.
Together, these findings help us to better understand the
mechanisms underlying chondrogenesis and will be
instrumental in further dissecting gene regulatory mech-
anisms in skeletal pattern formation, endochondral
ossification and chondrocyte function.
Methods
Cartilage specimen collection and RNA isolation
Under a UCLA IRB-approved human subjects protocol,
five independent 14–18 week distal human femur growth
plate cartilage samples were obtained with informed
consent. RNA was isolated and purified from the tissue as
previously described [96]. Briefly, the fetal cartilage was
digested in 0.3% bacterial collagenase, the chondrocytes
were collected by centrifugation and total RNA was
isolated with TRIZol (Thermo Fisher Scientific). Genomic
DNA contamination was removed by DNase I (Thermo
Fisher Scientific) digestion and the RNA was further
purified with the RNeasy Mini Kit (Qiagen). All of the
RNA samples had RIN (RNA Integrity Number) ≥8 (mea-
sured with the Agilent 2100 BioAnalyzer).
Gene expression analysis
PolyA-tailed mRNA was isolated from total RNA and
used as the input for sequencing library construction
with the TruSeq RNA Preparation Kit (Illumina).
Sequencing was performed on the Illumina HiSeq 2000
instrument (Additional file 1: Dataset S1). The sequen-
cing data analysis pipeline was described previously [97].
Briefly, RNA-seq reads were mapped to the human gen-
ome (hg19) using TopHat (v2.0.9), allowing up to 2-bp
mismatches per read [98]. The mapped reads were
analyzed using the Cufflinks (v2.2.1) package [99]. The
transcript abundance in each sample was quantified with
Cuffquant. The Cuffquant outputs for all samples were
then joined and normalized with Cuffnorm. Gene
expression level is represented as FPKM (fragments per
kilobase of exon per million fragments mapped) values.
Refseq gene annotation was obtained from the UCSC
genome website (https://genome.ucsc.edu/). LncRNA
gene annotation was downloaded from GENCODE
[100]. Low abundance genes with FPKM values less than
1 were filtered before downstream analysis.
Identification of cartilage-selective (CS) genes
The PaGeFinder program has been used to define gene
expression patterns from high-throughput transcrip-
tomic data, which applies cosine similarity measure-
ments to discover housekeeping and tissue-specific/
selective genes [101]. The specificity measure (SPM)
value produced by PaGeFinder was used as a criterion to
estimate the relative expression specificity of a gene in a
given sample. To identify CS genes, gene expression
FPKM values from multiple samples within the same
tissue/cell type were averaged, yielding a table with aver-
age FPKM values for all measured genes. The data were
then processed with PaGeFinder and SPM values were
generated. CS genes were defined as the subset of genes
with average FPKM values ≥1 and SPM ≥0.9 in cartilage
samples. For the cartilage-selective lncRNAs, to elimin-
ate false-positives, lncRNAs that had sense strand exonic
overlap with expressed protein-coding genes or that
were embedded in gene introns for which there was
intron-retention, were excluded from the cartilage-
selective lncRNA list.
External data sources
The data used in this study are summarized in
Additional file 1: Dataset S1. Some of the RNA-seq data
from normal human tissues/cells have been reported by
others [17–23]. Histone modification ChIP-seq data
were downloaded from the NCBI epigenome roadmap
project (http://www.ncbi.nlm.nih.gov/geo/roadmap/epi-
genomics/) [20]. Processed alignment files for histone
ChIP-seq in human fetal tissues were also downloaded
from the epigenome roadmap project website (http://
egg2.wustl.edu/roadmap/data/byFileType/alignments/cons
olidated/). Genome-wide SOX9 binding data in mouse
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chondrocytes were described previously [52]. All down-
loaded data were processed using the UCSC hg19 build.
ChIP-seq data processing
Bowtie 0.12.7 was used to align sequenced reads to the
human (hg19, for histone modifications) and murine
genomes (mm9, for SOX9 ChIP-seq). Reads that aligned
to more than one genomic location or that had more
than 2 mismatches were discarded. The human genome
was divided into 100 bp windows and peak calling was
performed with MACS (v1.3.7.1) using its default
P-value [102].
Prediction of active enhancers
Active enhancers were predicted based on H3K27ac
ChIP-seq peaks that were >3 kb away from gene tran-
scription start sites (TSS) and H3K4me3 peaks (a marker
for active promoters) [55]. Enhancers within 1 kb of
each other were merged. Chondrocyte-unique enhancers
were defined as the enhancers only detected in chondro-
cytes in comparison with other tissues.
Gene ontology (GO) and network analysis
CS genes were submitted to DAVID for GO and KEGG
pathway analysis [103]. GO analysis for chondrocyte-
unique enhancers was performed with the Genomic
Regions Enrichment of Annotations Tool (GREAT)
using default settings [56]. Genome coordinates for CS
lncRNAs were submitted to GREAT and protein coding
genes flanking lncRNA loci were identified. Gene net-
work analysis was performed with Cytoscape 3.2.1, using
plug-ins ClueGO and GeneMANIA [31, 104, 105].
Motif analysis
Enrichment analysis of known transcription factor bind-
ing motifs was performed with SeqPos [106] using DNA
sequences from gene promoter regions (±2 kb from
TSS) or enhancers.
Data processing and visualization
Heatmaps, boxplots and scatter plots were generated
with R. Sequencing data were visualized with the Inte-
grated Genome Browser [107].
Additional files
Additional file 1: Supplementary Dataset S1. Data used in the study.
(XLSX 17 kb)
Additional file 2: Figure S1. Dendrogram and heatmap of the
Pearson’s correlation coefficient for human tissue gene expression
(Log2FPKM). Only genes with FPKM > 1 in at least one sample were used
for analysis. The cartilage samples are highlighted with a red frame.
Figure S2. Box plots showing cartilage-selective gene expression in
cartilage (red) and non-cartilage (blue) tissues. The thick horizontal line in
each box represents the median gene expression value. Figure S3. Bar
graph showing RUNX2 expression in human tissues. Red bars indicate cartilage
samples and blue bars indicate non-cartilage samples, respectively. Gene
expression levels are shown as FPKM values. Figure S4. Genome browser
views of H3K4me1 and H3K27ac peaks along a COL2A1 and b COL11A1 loci.
Chromosome coordinates are shown as black bars on top. Black arrows
indicate the direction of transcription on a diagram of each gene below. CH,
chondrocytes. AG, adrenal gland. LI, large intestine. SI, small intestine. MU,
muscle. SC, spinal cord. ST, stomach. TH, thymus. Figure S5. Genome browser
views of H3K4me1, H3K4me3, H3K27ac peaks and RNA expression track along
lncRNA loci (A) AC058791.1 and (B) RP11–261P24.2 in human chondrocytes.
Figure S6. Sox9 binds to the lncRNA 2610035D17Rik promoter and gene body
in mouse rib chondrocytes. a Genome browser view of Sox9 binding along
Sox9 and 2610035D17Rik loci on chromosome 11. b Shaded region in a was
enlarged for a close view of Sox9 binding at the 2610035D17Rik promoter and
first intron. (PDF 912 kb)
Additional file 3: Supplementary Dataset S2. Cartilage-selective genes.
(XLSX 45110 kb)
Additional file 4: Supplementary Dataset S3. Data comparison between
microarray and RNA-seq platforms. (XLSX 8 kb)
Additional file 5: Supplementary Dataset S4. Cartilage-selective tran-
scription factors and motif analysis. (XLSX 26 kb)
Additional file 6: Supplementary Dataset S5. GO analysis of cartilage-
unique enhancers. (XLSX 1028 kb)
Additional file 7: Supplementary Dataset S6. Cartilage selective lncRNAs.
(XLSX 17845 kb)
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